The oral hypoglycemic agents used in the management therapies for DM must improve the pathophysiology by increasing insulin secretion and/or sensitivity, as well as inhibit hepatic glucose production via the downregulation of gluconeogenesis (DeFronzo et al., 1992; Wilson et al., 2011; Nithya and Subramanian, 2015; Nithya et al., 2017). This evidence concerns the gene INS and diabetes mellitus.